PCI Biotech Holding ASA (0JGL) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to PCI Biotech's second half-year 2024 presentation, which also includes preliminary numbers for the entire year. My name is Ronny Skugedal, and I am the CEO and CFO of the company. With me today is Morten Lur, our newly established CSO. Please take our important notice and disclaimer. The agenda for today is the operational review that Morten will take us through regarding the bioprocess, a little about finance and outlook, and finally a question and answer round, where it will be possible to send in questions via the webcast console. Let's start early and on the way, so that we have the questions in hand when we get that far. Then I hand over the floor to Morten. Good morning. PCI Biotech develops new technology with the aim of increasing productivity in the production of AAV gene therapy to make these treatments more accessible. Good morning, and welcome to PCI Biotech's second half-year 2024 presentation, which also includes preliminary numbers for the entire year. My name is Ronny Skuggerdal, and I am the CEO and CFO of the company. With me today is Morten Lur, our newly established CSO. Please take our important notice and disclaimer. The agenda for today is the operational review that Morten will take us through regarding the bioprocess, a little about finance and outlook, and finally a question and answer round, where it will be possible to send in questions via the webcast console. Please start early and on the way, so that we have the questions in hand when we get that far. Then I give the floor to Morten. Good morning. PCI Biotech develops new technology with the aim of increasing productivity in the production of AAV gene therapy to make these treatments more accessible. AAV gene therapy is based on an adeno-associated virus, sho...